Clinical Research Directory

Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis

Sponsor: Vertex Pharmaceuticals Incorporated

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA in healthy participants. The study will also evaluate the safety, tolerability, and pharmacokinetics of VX-581 administered in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).

Official title: A Phase 1 Study of VX-581 in Healthy Subjects and in Subjects With Cystic Fibrosis

Key Details

Conditions

Interventions

Locations (1)